Public Profile

Loxo

Loxo Oncology, a prominent player in the biopharmaceutical industry, is headquartered in the United States and focuses on the development of targeted therapies for cancer treatment. Founded in 2013, the company has made significant strides in precision medicine, particularly in the field of oncology, with a commitment to addressing unmet medical needs. Loxo Oncology is renowned for its innovative approach to drug development, offering unique therapies that target specific genetic mutations in tumours. Their core products, including the well-regarded Vitrakvi (larotrectinib), exemplify their dedication to personalised medicine, setting them apart in a competitive market. With a strong presence in the US and expanding operations globally, Loxo has established itself as a leader in the oncology sector, achieving notable milestones in clinical trials and regulatory approvals.

DitchCarbon Score

How does Loxo's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

13

Industry Average

Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

14

Industry Benchmark

Loxo's score of 13 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.

58%

Loxo's reported carbon emissions

Loxo, headquartered in the US, has not disclosed specific carbon emissions data for recent years. The latest available emissions data dates back to 2017, where the company reported specific greenhouse gas emissions of approximately 0.04626 kg CO2e per €1,000 in revenue. This figure reflects the company's performance in managing its carbon footprint relative to its revenue generation. Currently, Loxo has not set any formal reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to the Science Based Targets initiative (SBTi). This lack of specific climate pledges suggests that Loxo may be in the early stages of developing a comprehensive climate strategy. In the context of the industry, many companies are increasingly focusing on reducing their carbon emissions and committing to sustainability goals. As Loxo navigates its climate commitments, it may consider aligning with industry standards to enhance its environmental impact and transparency.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Loxo's primary industry is Chemicals nec, which is medium in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. Loxo is headquartered in US, which has a rank of low, indicating low grid carbon intensity.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Loxo is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero

Similar Organizations

Genzyme Corporation, Inc.

US
Health and social work services (85)
Updated about 1 month ago
DitchCarbon Score

Blueprint Medicines

US
Education services (80)
Updated 21 days ago

F. Hoffmann-La Roche AG

CH
Food waste for treatment: composting and land application
Updated 10 days ago
DitchCarbon Score

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers